Under the updated protocol, routine biennial prostate-specific antigen screenings are advised for individuals aged 50 to 69 to address severe health disparities. Recent research has restored clinical confidence in PSA as an effective biomarker, moving past previous concerns regarding testing specificity. Clinicians specifically hope the proactive guidance will decrease the number of Black men diagnosed with advanced prostate cancer, given their historical overrepresentation in fatal outcomes.
Key points
The revised screening protocol seeks to drastically reduce late-stage diagnoses among dis…: The revised screening protocol seeks to drastically reduce late-stage diagnoses among disproportionately affected Black patients.
Restored faith in the specificity of PSA testing prompted the establishment of regular bi…: Restored faith in the specificity of PSA testing prompted the establishment of regular biennial screening intervals.
Targeted screening protocols reflect an ongoing medical push to mitigate disparate mortal…: Targeted screening protocols reflect an ongoing medical push to mitigate disparate mortality rates in high-risk populations.
Sources checked by our analysis pipeline: 1
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here.
Happy Thursday. We’ve got a great lineup for you today, including an inside look at shuffles within the Senate’s health committee, and what it might mean for “Medicare for All.”
Experts update prostate cancer risk in adult men
Are you an American man between 50 and 69? You might want to get checked for prostate cancer.
The American Cancer Society released a major update to its guidelines today, recommending testing for prostate-specific antigen blood levels every two years, especially in high risk groups like Black men and men with a significant history of prostate cancer in the family. The guideline’s authors hope that increased surveillance will reduce the number of Black patients presenting with cancers at advanced stages, as this demographic is disproportionately represented in prostate cancer mortality.
The changes reflect renewed attention to PSA as a reliable biomarker. It had fallen out of favor for its lack of specificity before recent findings returned it to specialists’ good graces. Read more…
Tens of thousands of school-age children across the UK face chronic exhaustion and severe social isolation as they juggle extensive domestic duties with their education. Advocacy groups warn that official statistics drastically underestimate the scale of this hidden demographic. In response, regional authorities are revising support frameworks to safeguard these youths from falling behind academically and socially.
International aid shortfalls have left frontline medical responders without pay, fuel, and vital supplies while fighting the second deadliest Ebola outbreak on record in the Democratic Republic of Congo. The crisis is compounded by the Bundibugyo species of the virus, which lacks approved vaccines or treatments and has already claimed over 5,400 lives. Health agencies warn that extreme financial opacity is allowing transmission to accelerate unchecked across multiple central and east African borders.
Pharmaceutical giants are pouring substantial capital into immunization research because emerging scientific data reveals potential breakthroughs far beyond traditional infectious disease prevention. These massive investments target advanced applications, including oncology treatments and long-term neurological health, which promise to reshape medical care.